| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | September 13, 2024 4:00 P.M. |
| Form: | S-1 | ||||||
| |||||||
Save time and jump to the most important pieces.
4 - IMPACT BIOMEDICAL INC. (0001834105) (Issuer)
4 - IMPACT BIOMEDICAL INC. (0001834105) (Issuer)
4 - IMPACT BIOMEDICAL INC. (0001834105) (Issuer)
4 - IMPACT BIOMEDICAL INC. (0001834105) (Issuer)
3/A - IMPACT BIOMEDICAL INC. (0001834105) (Issuer)
8-K - IMPACT BIOMEDICAL INC. (0001834105) (Filer)
8-K - IMPACT BIOMEDICAL INC. (0001834105) (Filer)
8-K - IMPACT BIOMEDICAL INC. (0001834105) (Filer)
HOUSTON, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE:IBO), a pioneering biotechnology company dedicated to discovering, developing, and patenting innovative healthcare solutions, is pleased to announce the successful completion of its Initial Public Offering (IPO). Notable is that over 30% of the IPO was purchased by existing investors which further demonstrates strong belief in the company and its potential. Frank D. Heuszel, CEO of Impact BioMedical, commented, "The significant participation of our investors underscores their confidence in our mission and the innovative healthcare solutions we are developing. Their support is a testament to the value they see in our w
HOUSTON, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. ("IBO") is pleased to announce that the US Patent and Trademark Office has issued U.S. Patent No. 11,985,973 entitled "Insect Repelling Composition" developed within IBO's 3F™ technology platform. This is in addition to IBO's prior granted U.S. Patent No. 11,246,310. Both patents include compositions and formulations of constituents found in plants and fragrances produced by plants, which, when applied as a natural insect repellent, have the potential to reduce insect landings and bites experienced in an outdoor environment. The terms of U.S. Patents 11,985,973 and 11,246,310 will expire in February 2039 and April 2040, re
NEW YORK, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE:IBO), a pioneering biotechnology company dedicated to discovering, developing, and patenting unique healthcare solutions, is pleased to introduce its executive leadership team, poised to lead the company through its next phase of innovation and growth. "We are excited to introduce our exceptional leadership team, which brings together a wealth of experience and a shared vision for driving innovation and growth at Impact BioMedical," said Jason Grady, Impact Biomedical's Director, and Interim CEO of DSS, Inc. "With their expertise and commitment, we are confident in our ability to advance our mission and deliver